Expert Review of Anti-infective Therapy最新文献_第8页

Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications. 依拉维辛：体外活性、临床疗效和实际应用的全面回顾。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-06-01 Epub Date: 2024-05-08 DOI: 10.1080/14787210.2024.2351552

Po-Yu Huang, Chi-Kuei Hsu, Hung-Jen Tang, Chih-Cheng Lai

{"title":"Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications.","authors":"Po-Yu Huang, Chi-Kuei Hsu, Hung-Jen Tang, Chih-Cheng Lai","doi":"10.1080/14787210.2024.2351552","DOIUrl":"10.1080/14787210.2024.2351552","url":null,"abstract":"Introduction: The escalating threat of multidrug-resistant organisms necessitates constant exploration for novel antimicrobial agents. Eravacycline has emerged as a promising solution due to its unique chemical structure, which enhances potency and expands its spectrum of activity.Area covered: This review provides a thorough examination of eravacycline, encompassing its in vitro activity against Gram-positive and Gram-negative aerobes, carbapenem-non-susceptible organisms, anaerobes, and other bacterial strains. Additionally, it evaluates evidence from clinical studies to establish its clinical effect and safety.Expert opinion: Eravacycline, a synthetic fluorocycline, belongs to the tetracyclines class. Similar to other tetracycline, eravacycline exerts its antibacterial action by reversibly binding to the bacterial ribosomal 30S subunit. Eravacycline demonstrates potent in vitro activity against many Gram-positive and Gram-negative aerobes, anaerobes, and multidrug-resistant organisms. Randomized controlled trials and its associated meta-analysis affirm eravacycline's efficacy in treating complicated intra-abdominal infections. Moreover, real-world studies showcase eravacycline's adaptability and effectiveness in diverse clinical conditions, emphasizing its utility beyond labeled indications. Despite common gastrointestinal adverse events, eravacycline maintains an overall favorable safety profile, reinforcing its status as a tolerable antibiotic. However, ongoing research is essential for refining eravacycline's role, exploring combination therapy, and assessing its performance against biofilms, in combating challenging bacterial infections.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"387-398"},"PeriodicalIF":5.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovative strategies for the surveillance, prevention, and management of pediatric infections applied to low-income settings. 适用于低收入环境的儿科感染监测、预防和管理创新战略。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-06-01 Epub Date: 2024-05-17 DOI: 10.1080/14787210.2024.2354839

David Torres-Fernandez, Jessica Dalsuco, Justina Bramugy, Quique Bassat, Rosauro Varo

{"title":"Innovative strategies for the surveillance, prevention, and management of pediatric infections applied to low-income settings.","authors":"David Torres-Fernandez, Jessica Dalsuco, Justina Bramugy, Quique Bassat, Rosauro Varo","doi":"10.1080/14787210.2024.2354839","DOIUrl":"10.1080/14787210.2024.2354839","url":null,"abstract":"Introduction: Infectious diseases still cause a significant burden of morbidity and mortality among children in low- and middle-income countries (LMICs). There are ample opportunities for innovation in surveillance, prevention, and management, with the ultimate goal of improving survival.Areas covered: This review discusses the current status in the use and development of innovative strategies for pediatric infectious diseases in LMICs by focusing on surveillance, diagnosis, prevention, and management. Topics covered are: Minimally Invasive Tissue Sampling as a technique to accurately ascertain the cause of death; Genetic Surveillance to trace the pathogen genomic diversity and emergence of resistance; Artificial Intelligence as a multidisciplinary tool; Portable noninvasive imaging methods; and Prognostic Biomarkers to triage and risk stratify pediatric patients.Expert opinion: To overcome the specific hurdles in child health for LMICs, some innovative strategies appear at the forefront of research. If the development of these next-generation tools remains focused on accessibility, sustainability and capacity building, reshaping epidemiological surveillance, diagnosis, and treatment in LMICs, can become a reality and result in a significant public health impact. Their integration with existing healthcare infrastructures may revolutionize disease detection and surveillance, and improve child health and survival.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"413-422"},"PeriodicalIF":5.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140915980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An assessment of the index of rational drug prescribing for severe acute respiratory infections among hospitalised children in Northern Nigeria: a retrospective study. 尼日利亚北部住院儿童严重急性呼吸道感染合理用药指数评估：一项回顾性研究。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-06-01 Epub Date: 2024-02-09 DOI: 10.1080/14787210.2024.2307913

Aliyu Sulaiman, Mohammad Alfa Isah, Abubakar Usman

{"title":"An assessment of the index of rational drug prescribing for severe acute respiratory infections among hospitalised children in Northern Nigeria: a retrospective study.","authors":"Aliyu Sulaiman, Mohammad Alfa Isah, Abubakar Usman","doi":"10.1080/14787210.2024.2307913","DOIUrl":"10.1080/14787210.2024.2307913","url":null,"abstract":"Background: This study evaluated drug use pattern among hospitalized children with severe acute respiratory infection (SARI) in Nigeria.Research design and methods: A retrospective assessment of prescribed medicines for children aged 13 years and below who were admitted and treated for SARI from 1 January 2016 to 31 December 2018 was conducted. The WHO prescribing indicators and the Index of Rational Drug Prescribing were used to evaluate prescriptions.Results: A total of 259 patients were included, mostly diagnosed with bronchopneumonia (56%). A summary of WHO-core prescribing indicators showed the average number of drugs per encounter was 3.9, medicines prescribed by generic name was 82.1%, and an encounter with at least an antibiotic was 99.7%. The percentage of drugs prescribed from the Essential Medicine List for children was 79%. The most frequently prescribed pharmacological class of medicines was antibiotics (41.4%). Cephalosporins (40.0%), aminoglycosides (34.1%), and penicillins (21.5%) were the most commonly prescribed antibiotic classes. Gentamicin (34.1%) and cefuroxime (21.5%) were the most commonly prescribed antibiotics.Conclusions: Drug prescribing for hospitalized children with SARI was suboptimal, especially with regard to polypharmacy, antibiotics, and injection use. Interventions to promote rational use of medicines including antimicrobial stewardship interventions are recommended.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"479-486"},"PeriodicalIF":5.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients. 在艾滋病毒合并感染患者中使用泛基因型方案抗病毒治疗 HCV 感染的实际效果。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-16 DOI: 10.1080/14787210.2024.2353691

Anna Piekarska, Aleksandra Berkan-Kawińska, Hanna Berak, Włodzimierz Mazur, Marek Sitko, Anna Parfieniuk-Kowerda, Beata Lorenc, Dorota Dybowska, Ewa Janczewska, Justyna Janocha-Litwin, Beata Dobracka, Łukasz Socha, Magdalena Tudrujek-Zdunek, Robert Flisiak

{"title":"Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients.","authors":"Anna Piekarska, Aleksandra Berkan-Kawińska, Hanna Berak, Włodzimierz Mazur, Marek Sitko, Anna Parfieniuk-Kowerda, Beata Lorenc, Dorota Dybowska, Ewa Janczewska, Justyna Janocha-Litwin, Beata Dobracka, Łukasz Socha, Magdalena Tudrujek-Zdunek, Robert Flisiak","doi":"10.1080/14787210.2024.2353691","DOIUrl":"10.1080/14787210.2024.2353691","url":null,"abstract":"Background: The aim of this study was to evaluate the real-life efficacy of pangenotypic antivirals in HIV-HCV-positive patients.Research design and methods: The analysis included 5650 subjects who were treated with pangenotypic anti-HCV drugs: 5142 were HCV-positive and 508 were HIV-HCV-positive.Results: Patients with HCV-monoinfection were older (p < 0.0001), however patients with HCV-monoinfection had a higher proportion of advanced fibrosis F4 (p < 0.0001). There were no differences between the study groups in the rate of SVR12 in ITT-analysis (87,6% versus 93,9% in coinfection and monoinfection group, respectively; p > 0.05). However, there was a difference between study groups in PP-analysis, HIV/HCV and HCV, respectively 95.9% vs 97.9%, p = 0.0323. Additionally, there were a higher rate of patients who did not apply for follow-up (SVR12) in coinfected patients (7,9% vs 3,6% respectively p = 0.0001). In multivariante analysis, factors associated with worse response to the pangenotypic anti-HCV therapy included male sex, HCV genotype 3, stage of fibrosis and decompensation of liver function and HIV coinfection.Conclusions: The real-life results of pangenotypic anti-HCV treatment are veryeffective in the group of HIV-HCV-coinfected patients. However, the finaleffectiveness is slightly lower than that obtained in HCV monoinfectedpatients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-6"},"PeriodicalIF":5.7,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monotherapy versus combination for the treatment of Stenotrophomonas maltophilia: a multicenter cohort study. 单药与联合用药治疗嗜麦芽霉单胞菌病：一项多中心队列研究。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-13 DOI: 10.1080/14787210.2024.2353704

Thamer A Almangour, Hussain A Alali, Zakiyah Alkherb, Shuroug A Alowais, Khalid Bin Saleh, Sara Almuhisen, Abdullah Almohaizeie, Renad Alsahli, Shatha Alruwaite, Fai Alnashmi, Lolwa Fetyani, Noran Ibrahim Abouobaid, Alnajla Alghofaily, Khalifa M Binkhamis, Yazed Saleh Alsowaida

{"title":"Monotherapy versus combination for the treatment of Stenotrophomonas maltophilia: a multicenter cohort study.","authors":"Thamer A Almangour, Hussain A Alali, Zakiyah Alkherb, Shuroug A Alowais, Khalid Bin Saleh, Sara Almuhisen, Abdullah Almohaizeie, Renad Alsahli, Shatha Alruwaite, Fai Alnashmi, Lolwa Fetyani, Noran Ibrahim Abouobaid, Alnajla Alghofaily, Khalifa M Binkhamis, Yazed Saleh Alsowaida","doi":"10.1080/14787210.2024.2353704","DOIUrl":"https://doi.org/10.1080/14787210.2024.2353704","url":null,"abstract":"Background: The aim of this study was to compare the safety and effectiveness of monotherapy versus combination therapy for the treatment of infections caused by S. maltophilia.Methods: This retrospective, multicenter, cohort study included patients treated with either monotherapy or combination therapy for infections caused by S. maltophilia. Primary outcomes included overall in-hospital mortality, 30-day mortality, and clinical cure. Safety outcomes were also evaluated. Multivariable logistic regression was used as a control for confounding variables.Results: A total of 407 patients were included, 330 patients received monotherapy and 77 patients received combination therapy. A total of 21% presented with concomitant bacteremia. After adjusting the differences between the two groups, there were no statistically significant differences between patients who received monotherapy versus combination therapy in clinical cure (55% vs 65%; OR, 0.72; 95% CI, 0.40-1.31) and overall in-hospital mortality (52% vs 49%; OR, 0.84; 95% CI, 0.45-1.57). However, patients who received monotherapy had a lower rate of 30-day mortality (28% vs 32%; OR, 0.45; 95% CI, 0.22-0.90) and acute kidney injury (9% vs 18%; OR, 0.35; 95% CI, 0.16-0.78).Conclusion: Clinical outcomes did not significantly differ in patients who received combination therapy versus monotherapy. More data are needed to validate these findings.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":5.7,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140910731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical effectiveness of nirmatrelvir plus ritonavir for patients with COVID-19 and preexisting psychiatric disorders. 尼马瑞韦加利托那韦对 COVID-19 和原有精神障碍患者的临床疗效。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-11 DOI: 10.1080/14787210.2024.2351555

Ting-Hui Liu, Jheng-Yan Wu, Po-Yu Huang, Wan-Hsuan Hsu, Min-Hsiang Chuang, Ya-Wen Tsai, Chih-Cheng Lai, Charles Lung-Cheng Huang

{"title":"Clinical effectiveness of nirmatrelvir plus ritonavir for patients with COVID-19 and preexisting psychiatric disorders.","authors":"Ting-Hui Liu, Jheng-Yan Wu, Po-Yu Huang, Wan-Hsuan Hsu, Min-Hsiang Chuang, Ya-Wen Tsai, Chih-Cheng Lai, Charles Lung-Cheng Huang","doi":"10.1080/14787210.2024.2351555","DOIUrl":"10.1080/14787210.2024.2351555","url":null,"abstract":"Objectives: This study assessed the clinical effectiveness of the combination of nirmatrelvir and ritonavir (NMV-r) in treating nonhospitalized patients with COVID-19 who have preexisting psychiatric disorders.Methods: Patients diagnosed with COVID-19 and psychiatric disorders between 1 March 2020, and 1 December 2022, were included using the TriNetX network. The primary outcome was the composite outcome of all-cause emergency department (ED) visits, hospitalization, or death within 30 days.Results: Propensity score matching yielded two cohorts of 20,633 patients each. The composite outcome of all-cause ED visits, hospitalization, or death within 30 days was 3.57% (737 patients) in the NMV-r cohort and 5.69% (1176) in the control cohort, resulting in a reduced risk in the NMV-r cohort (HR: 0.657; 95% confidence interval (CI): 0.599-0.720). The NMV-r cohort exhibited a lower risk of all-cause hospitalization (HR: 0.385; 95% CI: 0.328-0.451) and all-cause death (HR: 0.110; 95% CI: 0.053-0.228) compared with the control group.Conclusion: NMV-r could mitigate the risk of adverse outcomes in nonhospitalized patients with COVID-19 and preexisting psychiatric disorders. However, only a limited number of patients in this population received adequate treatment, thus emphasizing the importance of promoting its appropriate use.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":5.7,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre-existing chronic obstructive pulmonary diseases. 最近批准的口服抗病毒药物对轻度至中度 COVID-19 和原有慢性阻塞性肺病患者疗效的影响。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-08 DOI: 10.1080/14787210.2024.2351571

Bo-Wen Shiau, Wan-Hsuan Hsu, Ya-Wen Tsai, Jheng-Yan Wu, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai, Lih-Wen Jang

{"title":"Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre-existing chronic obstructive pulmonary diseases.","authors":"Bo-Wen Shiau, Wan-Hsuan Hsu, Ya-Wen Tsai, Jheng-Yan Wu, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai, Lih-Wen Jang","doi":"10.1080/14787210.2024.2351571","DOIUrl":"10.1080/14787210.2024.2351571","url":null,"abstract":"Objectives: This study assessed the effectiveness of the oral antiviral agents nirmatrelvir - ritonavir (NMV-r) and molnupiravir (MOV) for treating mild-to-moderate coronavirus disease 2019 (COVID-19) in patients with COPD.Methods: This retrospective cohort study extracted data from the TriNetX platform and examined 94,984 COVID-19 patients with preexisting COPD from 1 January 2022, to 1 October 2023. Patients receiving NMV-r or MOV (study group) were compared with those not receiving oral antiviral agents (control group) after propensity score matching (PSM).Results: After PSM, 7,944 patients were classified into the study and control groups. The primary composite outcome of all-cause hospitalization, or death in 30 days was reported in 458 (5.7%) patients in the study group and 566 (7.1%) patients in the control cohort, yielding a hazard ratio [HR] of 0.79 (95% confidence interval [CI]: 0.70-0.89; Table 2). Compared with the control group, the study group had a significantly lower risk of all-cause hospitalization (HR, 0.87; 95% CI: 0.76-0.99) and death (HR: 0.21, 95% CI: 0.13-0.35).Conclusions: This study revealed that oral antivirals - NMV-r or MOV might improve clinical outcomes in patients with preexisting COPD and COVID-19. However, only a small proportion of preexisting COPD patients with COVID-19 received oral antiviral treatment.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":5.7,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140850983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond resistance: assessing sulbactam-Durlobactam’s role in Today’s clinical landscape 超越耐药性：评估舒巴坦-杜鲁巴坦在当今临床中的作用

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-02 DOI: 10.1080/14787210.2024.2351026

Ahmad Z. Al Meslamani

引用次数: 0

Clostridioides difficile infection in inflammatory bowel disease: a clinical review 炎症性肠病中的艰难梭菌感染：临床综述

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-02 DOI: 10.1080/14787210.2024.2347955

Mengjun Tang, Chunhua Wang, Ying Xia, Jian Tang, Jiao Wang, Liang Shen

引用次数: 0

Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China. 基于中国一项多中心、大规模、回顾性队列研究的 MDR/RR-TB 治疗结果优化药物建议。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-01 Epub Date: 2024-01-22 DOI: 10.1080/14787210.2024.2303032

Lin Fan, Ming Yang, Yu-Tong Han, Fei Ren, Hua Wang, Jin-Bao Ma, Guo-Hui Zhu, Yan-Jun Xiong, Xin-Xin Fan, Su-Xia Chen, Hao-Yu Wu, Wen-Wen Sun, Shao-Jun Zhang, Hui Ke, Xiao-Hong Cheng, Biao Xu, Yu Chen, Chang Chen

{"title":"Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China.","authors":"Lin Fan, Ming Yang, Yu-Tong Han, Fei Ren, Hua Wang, Jin-Bao Ma, Guo-Hui Zhu, Yan-Jun Xiong, Xin-Xin Fan, Su-Xia Chen, Hao-Yu Wu, Wen-Wen Sun, Shao-Jun Zhang, Hui Ke, Xiao-Hong Cheng, Biao Xu, Yu Chen, Chang Chen","doi":"10.1080/14787210.2024.2303032","DOIUrl":"10.1080/14787210.2024.2303032","url":null,"abstract":"Objective: With the change in drug-resistant pattern, MDR/RR-TB was faced with underlying changes in regimens. A multi-center, large-scale, retrospective study performed aims to provide a recommendation of drug selection on optimization of outcome for the patients.Method: The study was conducted in six TB-specialized hospitals in China. Patients were included from 2018-2021 and followed up throughout the treatment. Using a multivarariable and propensity score-matched logistic regression analysis, we evaluated associations between outcomes and drug use, as well as clinical characteritics.Results: Of 3112 patients, 74.29% had treatment sucess, 14.52% lost to follow-up, 9.67% failure, and 1.51% died. Treatment success was positively associated with Bedaquiline(Bdq), Linezolid(Lzd), and Cycloserin(Cs). Capreomycin(Cm) increased the risk of unfavorable outcomes. other drugs such as Amikacin(Amk) and clofazimine had no significant effect on outcomes. If isolates were susceptible to fluoroquinolones(FQs), FQs could decrease the risk of unfavorable outcomes.Conclusions: The recommendation order for the treatment of MDR/RR-TB is Bdq, Lzd, and Cs. FQs were decreased in use intensity. Injection drugs, whether Amk or Cm, are not recommended.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"353-363"},"PeriodicalIF":4.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0